X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (9) 9
oncology (8) 8
male (6) 6
female (5) 5
renal cell carcinoma (5) 5
sunitinib (5) 5
treatment outcome (5) 5
aged (4) 4
article (4) 4
cancer (4) 4
carcinoma, renal cell - drug therapy (4) 4
hematology, oncology and palliative medicine (4) 4
middle aged (4) 4
prognosis (4) 4
sorafenib (4) 4
antineoplastic agents - adverse effects (3) 3
carcinoma, renal cell (3) 3
hypertension (3) 3
interferon-alpha (3) 3
kaplan-meier estimate (3) 3
kidney neoplasms - drug therapy (3) 3
kidney neoplasms - pathology (3) 3
retrospective studies (3) 3
risk assessment (3) 3
risk factors (3) 3
urology & nephrology (3) 3
1st-line therapy (2) 2
abridged index medicus (2) 2
adrenocortical carcinoma (2) 2
adult (2) 2
aged, 80 and over (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - therapeutic use (2) 2
axitinib (2) 2
b7-h1 (2) 2
biomarker (2) 2
cancer-patients (2) 2
carcinoma (2) 2
carcinoma, renal cell - pathology (2) 2
carcinoma, renal cell - secondary (2) 2
care and treatment (2) 2
disease progression (2) 2
disease-free survival (2) 2
dosage and administration (2) 2
immunotherapy (2) 2
metastasis (2) 2
molecular targeted therapy (2) 2
neoplasm metastasis (2) 2
pazopanib (2) 2
phase-ii (2) 2
predictive value of tests (2) 2
targeted therapy (2) 2
treatment patterns (2) 2
urology (2) 2
vascular endothelial growth factor (2) 2
vascular endothelial growth factor a - antagonists & inhibitors (2) 2
abiraterone acetate (1) 1
abiraterone acetate - administration & dosage (1) 1
abiraterone acetate - therapeutic use (1) 1
ace inhibitors (1) 1
acid suppression (1) 1
adjuvant mitotane (1) 1
adrenal cortex neoplasms - drug therapy (1) 1
adrenal cortex neoplasms - pathology (1) 1
adrenal-cortical carcinoma (1) 1
adrenocortical carcinoma - drug therapy (1) 1
adrenocortical carcinoma - secondary (1) 1
adt+docetaxel (1) 1
adverse events (1) 1
age factors (1) 1
analysis (1) 1
angiogenesis inhibitor therapies (1) 1
angiogenesis inhibitors (1) 1
angiotensin receptor blockers (1) 1
angiotensin system inhibitors (1) 1
angiotensins - antagonists & inhibitors (1) 1
animals (1) 1
antibody (1) 1
antihypertensive agents (1) 1
antihypertensive agents - therapeutic use (1) 1
antihypertensive drugs (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
ar targeting agents (1) 1
bevacizumab - administration & dosage (1) 1
bevacizumab - adverse effects (1) 1
biological markers (1) 1
biomarkers, tumor - blood (1) 1
biopsy (1) 1
blood pressure (1) 1
blood pressure - drug effects (1) 1
blood-pressure (1) 1
body mass index (1) 1
bone (1) 1
cancer cells (1) 1
carcinoma, renal cell - blood (1) 1
carcinoma, renal cell - diagnosis (1) 1
carcinoma, renal cell - metabolism (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 311 - 319
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 493 - 493
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
BACKGROUND Vascular endothelial growth factor (VEGF)–targeted therapies are standard treatment for metastatic renal cell carcinoma (mRCC); however, toxicities... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 2017, Volume 15, Issue 6, pp. 724 - 732
Journal Article
Surgical Pathology Clinics, ISSN 1875-9181, 2015, Volume 8, Issue 4, pp. 657 - 662
Renal cell carcinoma (RCC) is a heterogeneous disease. A rigorous diagnostic assessment by a pathologist with close communication with the clinician provides... 
Clear cell | Biomarker | Prognosis | Biopsy | Renal cell carcinoma | Biomarkers, Tumor - blood | Diagnosis, Differential | Carcinoma, Renal Cell - pathology | Carcinoma, Renal Cell - diagnosis | Humans | Kidney Neoplasms - pathology | Kidney Neoplasms - diagnosis
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 02/2015, Volume 3, Issue 1, p. 3
Background: Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are still not well established. Programmed Death Ligand-1 (PD-L1)... 
PD-L1 | PD-1 inhibitors | Adrenocortical carcinoma | Immunotherapy | MITOTANE | TUMOR | ANTIBODY | IMMUNOLOGY | CELL CARCINOMA | GROWTH-FACTOR RECEPTOR | THERAPY | ONCOLOGY | PATHWAY | B7-H1 | KIDNEY | PD-1 | Immunohistochemistry | Carcinoma | Prognosis | Monoclonal antibodies | Development and progression | Cancer
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.